These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 1920138)

  • 1. Effect of potassium channel blockade on the anti-ischemic actions of mechanistically diverse agents.
    Sargent CA; Smith MA; Dzwonczyk S; Sleph PG; Grover GJ
    J Pharmacol Exp Ther; 1991 Oct; 259(1):97-103. PubMed ID: 1920138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-ischemic effects of the potassium channel activators pinacidil and cromakalim and the reversal of these effects with the potassium channel blocker glyburide.
    Grover GJ; McCullough JR; Henry DE; Conder ML; Sleph PG
    J Pharmacol Exp Ther; 1989 Oct; 251(1):98-104. PubMed ID: 2507775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potassium channel openers and blockers: do they possess proarrhythmic or antiarrhythmic activity in ischemic and reperfused rat hearts?
    Tosaki A; Szerdahelyi P; Engelman RM; Das DK
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1355-62. PubMed ID: 8263798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KATP channel modulation in working rat hearts with coronary occlusion: effects of cromakalim, cicletanine, and glibenclamide.
    Ferdinandy P; Szilvássy Z; Droy-Lefaix MT; Tarrade T; Koltai M
    Cardiovasc Res; 1995 Nov; 30(5):781-7. PubMed ID: 8595627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardioprotective effects of a novel calcium antagonist related to the structure of cromakalim.
    Grover GJ; Sleph PG; Dzwonczyk S; McCullough JR
    J Pharmacol Exp Ther; 1993 Oct; 267(1):102-7. PubMed ID: 8229736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetes and ATP-sensitive potassium channel openers and blockers in isolated ischemic/reperfused hearts.
    Tosaki A; Engelman DT; Engelman RM; Das DK
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1115-23. PubMed ID: 8531071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of cromakalim and glibenclamide on myocardial high energy phosphates and intracellular pH during ischemia-reperfusion: 31P NMR studies.
    Docherty JC; Gunter HE; Kuzio B; Shoemaker L; Yang L; Deslauriers R
    J Mol Cell Cardiol; 1997 Jun; 29(6):1665-73. PubMed ID: 9220352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic characterization of BMS-191095, a mitochondrial K(ATP) opener with no peripheral vasodilator or cardiac action potential shortening activity.
    Grover GJ; D'Alonzo AJ; Garlid KD; Bajgar R; Lodge NJ; Sleph PG; Darbenzio RB; Hess TA; Smith MA; Paucek P; Atwal KS
    J Pharmacol Exp Ther; 2001 Jun; 297(3):1184-92. PubMed ID: 11356945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cardioprotective and electrophysiological effects of cromakalim are attenuated by meclofenamate through a cyclooxygenase-independent mechanism.
    Grover GJ; D'Alonzo AJ; Sleph PG; Dzwonczyk S; Hess TA; Darbenzio RB
    J Pharmacol Exp Ther; 1994 May; 269(2):536-40. PubMed ID: 8182522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glyburide-reversible cardioprotective effect of BMS-180448 is independent of action potential shortening.
    Grover GJ; D'Alonzo AJ; Hess T; Sleph PG; Darbenzio RB
    Cardiovasc Res; 1995 Nov; 30(5):731-8. PubMed ID: 8595620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacologic profile of cromakalim in the treatment of myocardial ischemia in isolated rat hearts and anesthetized dogs.
    Grover GJ; Sleph PG; Dzwonczyk S
    J Cardiovasc Pharmacol; 1990 Dec; 16(6):853-64. PubMed ID: 1704976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardioprotective effects of the potassium channel opener cromakalim: stereoselectivity and effects on myocardial adenine nucleotides.
    Grover GJ; Newburger J; Sleph PG; Dzwonczyk S; Taylor SC; Ahmed SZ; Atwal KS
    J Pharmacol Exp Ther; 1991 Apr; 257(1):156-62. PubMed ID: 2019983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glyburide-sensitive K+ channels in cultured rat hippocampal neurons: activation by cromakalim and energy-depleting conditions.
    Politi DM; Rogawski MA
    Mol Pharmacol; 1991 Aug; 40(2):308-15. PubMed ID: 1715018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenosine triphosphate-sensitive potassium channel blocking agent ameliorates, but the opening agent aggravates, ischemia/reperfusion-induced injury. Heart function studies in nonfibrillating isolated hearts.
    Tosaki A; Hellegouarch A
    J Am Coll Cardiol; 1994 Feb; 23(2):487-96. PubMed ID: 8294705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations by glyburide of effects of BRL 34915 and P 1060 on contraction, 86Rb efflux and the maxi-K+ channel in rat portal vein.
    Hu SL; Kim HS; Okolie P; Weiss GB
    J Pharmacol Exp Ther; 1990 May; 253(2):771-7. PubMed ID: 2110977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific block of the anti-ischemic actions of cromakalim by sodium 5-hydroxydecanoate.
    McCullough JR; Normandin DE; Conder ML; Sleph PG; Dzwonczyk S; Grover GJ
    Circ Res; 1991 Oct; 69(4):949-58. PubMed ID: 1934346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardioprotection in ischemic rat hearts with the SH-containing angiotensin-converting enzyme inhibitor zofenopril: possible involvement of the ATP-sensitive potassium channel.
    Sargent CA; Sleph PG; Dzwonczyk S; Smith MA; Normandin D; Antonaccio MJ; Grover GJ
    J Pharmacol Exp Ther; 1993 May; 265(2):609-18. PubMed ID: 8496812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cardioprotective effect of cromakalim, a K+ channel opener, on isolated globally ischemic and reperfused rat hearts].
    Taki H; Masuda Y; Yoshizumi M; Kitagawa T; Katoh I
    Nihon Kyobu Geka Gakkai Zasshi; 1993 Mar; 41(3):438-44. PubMed ID: 8478573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of a pharmacologic interaction between ATP-sensitive potassium channels and adenosine A1 receptors in ischemic rat hearts.
    Grover GJ; Baird AJ; Sleph PG
    Cardiovasc Res; 1996 Apr; 31(4):511-7. PubMed ID: 8689642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potassium channel modulation: a new drug principle for regulation of smooth muscle contractility. Studies on isolated airways and arteries.
    Nielsen-Kudsk JE
    Dan Med Bull; 1996 Dec; 43(5):429-47. PubMed ID: 8960816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.